CA2113547A1 - Purine derivatives - Google Patents

Purine derivatives

Info

Publication number
CA2113547A1
CA2113547A1 CA002113547A CA2113547A CA2113547A1 CA 2113547 A1 CA2113547 A1 CA 2113547A1 CA 002113547 A CA002113547 A CA 002113547A CA 2113547 A CA2113547 A CA 2113547A CA 2113547 A1 CA2113547 A1 CA 2113547A1
Authority
CA
Canada
Prior art keywords
adenosine
chloro
propyl
phenoxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002113547A
Other languages
English (en)
French (fr)
Inventor
Lars J. S. Knutsen
Jesper Lau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2113547A1 publication Critical patent/CA2113547A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA002113547A 1992-05-14 1993-05-12 Purine derivatives Abandoned CA2113547A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK92626A DK62692D0 (hr) 1992-05-14 1992-05-14
DK0626/92 1992-05-14

Publications (1)

Publication Number Publication Date
CA2113547A1 true CA2113547A1 (en) 1993-11-25

Family

ID=8095717

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002113547A Abandoned CA2113547A1 (en) 1992-05-14 1993-05-12 Purine derivatives

Country Status (9)

Country Link
EP (1) EP0603348A1 (hr)
JP (1) JPH06508855A (hr)
AU (1) AU671995B2 (hr)
CA (1) CA2113547A1 (hr)
DK (1) DK62692D0 (hr)
FI (1) FI940167A (hr)
IL (1) IL105673A (hr)
NZ (1) NZ252110A (hr)
WO (1) WO1993023418A1 (hr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK155292D0 (da) * 1992-12-23 1992-12-23 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
US5589467A (en) * 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
BR9507683A (pt) * 1994-05-10 1997-09-23 Sandoz Ag Derivados de adenosina
EP0704215A3 (en) * 1994-06-02 1998-04-01 Takeda Chemical Industries, Ltd. Inhibitor of vascular permeability enhancer
GB9421133D0 (en) * 1994-10-20 1994-12-07 Glaxo Group Ltd Medicaments
US6110902A (en) * 1997-06-23 2000-08-29 Moehler; Hanns Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
CO5180581A1 (es) * 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
WO2001087843A1 (en) * 2000-05-15 2001-11-22 Novo Nordisk A/S Compounds for treating disorders where a decreased level of plasma ffa is desired
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
WO2007107598A1 (en) 2006-03-21 2007-09-27 Heinrich-Heine-Universität Düsseldorf Phosphorylated a2a receptor agonists
CZ2009298A3 (cs) * 2009-05-14 2010-11-24 Univerzita Palackého v Olomouci Substituované 6-benzylaminopurin ribosidy, jejich použití a farmaceutický prípravek tyto slouceniny obsahující
HUE030566T2 (en) 2010-01-11 2017-05-29 Inotek Pharmaceuticals Corp Combination, kit and method for reducing intraocular pressure
JP2013523738A (ja) * 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション アデノシン化合物およびそれらの使用
SG184221A1 (en) 2010-03-26 2012-10-30 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
MX2014009086A (es) 2012-01-26 2015-06-05 Inotek Pharmaceuticals Corp Polimorfos anhidros de nitrato de [ (2r,3s,4r,5r) -5- (6- (ciclopentilamino) -9h-purin-9-il) -3,4-dihidroxitetra-hidrofuran- 2-il) ] metilo y procesos para su preparación.
KR20150139501A (ko) 2013-03-15 2015-12-11 이노텍 파마슈티컬스 코포레이션 안과용 제형
JP2015172077A (ja) * 2015-06-24 2015-10-01 中国医学科学院葯物研究所 Ｎ６−置換アデノシン誘導体とｎ６−置換アデニン誘導体の鎮静、催眠、抗うつ、抗痙攣、抗てんかん、抗パーキンソン病と認知証予防・治療の用途
GB2582361A (en) * 2019-03-21 2020-09-23 Univ Warwick Adenosine receptor agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL128629C (hr) * 1966-05-07
DE1670077C3 (de) * 1966-05-07 1975-04-24 Boehringer Mannheim Gmbh, 6800 Mannheim Adenosin-Derivate und Verfahren zu ihrer Herstellung
NL6717061A (hr) * 1966-12-21 1968-06-24
DE2052596A1 (de) * 1970-10-27 1972-05-04 Boehringer Mannheim Gmbh, 6800 Mannheim Neuartige Verwendung von N(6)-substituierten Adenosin-Derivaten
DE3406533A1 (de) * 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
AU582359B2 (en) * 1984-04-18 1989-03-23 Nelson Research & Development Company N-6 substituted adenosine derivatives as cardiac vasodilators
US4791103A (en) * 1985-02-08 1988-12-13 Warner-Lambert Company 2,N6 -disubstituted adenosines, derivatives and methods of use
JPH0696534B2 (ja) * 1986-04-25 1994-11-30 ヘキストジヤパン株式会社 抗痴呆剤
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
DK62592D0 (hr) * 1992-05-14 1992-05-14 Novo Nordisk As

Also Published As

Publication number Publication date
AU671995B2 (en) 1996-09-19
FI940167A0 (fi) 1994-01-13
DK62692D0 (hr) 1992-05-14
IL105673A0 (en) 1993-09-22
AU4061293A (en) 1993-12-13
EP0603348A1 (en) 1994-06-29
IL105673A (en) 1998-01-04
NZ252110A (en) 1996-07-26
FI940167A (fi) 1994-03-03
JPH06508855A (ja) 1994-10-06
WO1993023418A1 (en) 1993-11-25

Similar Documents

Publication Publication Date Title
CA2113547A1 (en) Purine derivatives
KR100349385B1 (ko) 2-티오크산틴으로부터 얻어진 3-치환 아데닌
CA2414018C (en) 2-aminocarbonyl-9h-purine derivatives
SK4842002A3 (en) Purine derivatives
EP1030857A2 (en) Adenosine a1 receptor agonists
CS203093B2 (en) Method of preparing substituted purines
SK391891A3 (en) Xanthine derivatives and pharmaceutical composition comprising same
EP0256692B1 (en) 6-thioxanthines
AU657415B2 (en) Novel adenosine derivatives
US5578582A (en) Methods of treating ischemia with C2, N6 -disubstituted adenosine derivatives
AU4081493A (en) 8-substituted anthines as phosphodiesterase inhibitors
JPH10508032A (ja) アリールチオキサンチン類
EP1019404A1 (en) Purine acyclonucleosides as antiviral agents
US5672588A (en) Purine derivatives
US6306847B1 (en) Condensed purine derivatives
JP2005526106A (ja) ニトロベンジルチオイノシンの新規同族体
EP0799040B1 (en) Trisubstituted thioxanthines
AU740264C (en) Antiviral agents
JPH03218378A (ja) キサンチン誘導体
EP1395267A2 (en) Therapeutic compositions for modulating the immune response in a mammal and use thereof
JPH04128285A (ja) キサンチン誘導体
WO2005111053A2 (en) Pharmaceutical compositions having anti-inflammatory activity

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 19990512